In adults living with HIV, the 21-valent pneumococcal conjugate vaccine (PCV) V116 was well tolerated and effective against all 21 target serotypes. The immune responses were comparable to those ...
Findings showed Capvaxive was noninferior to PPSV23 for each of the 12 serotypes present between the 2 vaccines. Topline data were announced from a phase 3 trial evaluating Merck’s 21-valent ...
Merck's pneumococcal vaccine showed strong immune responses in children and teens who are at higher risk of serious illness in a late-stage study, the drugmaker said on Thursday. The shot, Capvaxive, ...
—Spanish investigators analyzed pneumococcal lineages among adults with invasive pneumococcal disease (IPD) and assessed how the emergence of nonvaccine serotypes has contributed to the burden of ...
Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 OPUS-1, VAX-31 ...
These data indicate that either alternative vaccine strategies or alternative strategies to protect these patients from pneumococcal disease are required,’ said Michael Chen-Xu, MD.
Approved 15 months ago as a pneumococcal disease vaccine for adults—and billed as the first shot designed for seniors—Merck’s Capvaxive now has data supporting its potential in children and ...
Using national data, researchers in England calculated the risk of invasive pneumococcal disease (IPD) among women ages 15 to 44 years old. With a few exceptions, there were no statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results